CAMBRIDGE MA., June 22, 2020 – Elicio Therapeutics, a next generation immuno-oncology company, announced today that Adrian Bot, MD, PhD, Vice President of Translational Medicine at Kite, a Gilead Company, has joined Elicio’s Scientific Advisory Board.
“Dr. Bot is one of the world’s leading innovators in engineered T cells and vaccine technology for oncology and autoimmune disease,” said Christopher Haqq, MD, PhD, Elicio Executive Vice President, Head of R&D and Chief Medical Officer “Elicio’s mission is to transform immunotherapy. As a board member, Dr. Bot will advise Elicio on the most successful translational strategies to establish a visionary immunotherapy pipeline.”
Dr. Bot has more than 20 years of experience in the biopharmaceutical industry and expertise in discovery, research and development of immunotherapies. As former Chief Scientific Officer of Kite Pharma Inc. and current Vice President of Translational Medicine at Kite, a Gilead Company, a biotechnology company developing genetically engineered T cell therapies, Dr. Bot has been providing scientific and translational research leadership to the company’s technologies and growing product pipeline. This included the development of a first-in-class Chimeric Antigen Receptor T cell therapy against Non-Hodgkin’s Lymphoma, a recent milestone in the field of cancer immunotherapy.
Before joining Kite Pharma Inc., Dr. Bot served as Vice President of Research at MannKind Corp., where he led the efforts to discover and advance through development a number of immunotherapies and targeted therapies for different cancer indications, including therapeutic vaccines for malignant melanoma. Prior to MannKind, he served as Director of Immunology at Allecure Corp. Director of Immunology at Alliance Pharmaceutical Corp., and Guest Scientist at the Scripps Research Institute in La Jolla, where he led the research and development of novel vaccine adjuvants and active immunotherapies for autoimmune and infectious diseases such as multiple sclerosis, type 1 diabetes and influenza.
“By joining Elicio’s Scientific Advisory Board, I am privileged to have an opportunity to contribute to the development of a novel class of powerful active immunotherapies based on cutting edge material sciences, with broad applicability across several disease categories” said Dr. Bot. “Realizing the full potential of immunotherapy will require an integrative approach, bringing together novel technologies with complementary mechanisms”.
Dr. Bot received his MD degree at the University of Medicine and Pharmacy in Timisoara, Romania and his PhD in Biomedical Sciences at Mount Sinai School of Medicine in New York. His past editorial leadership appointments include International Reviews of Immunology, Journal of Translational Medicineand Journal of Immunology.
About Elicio Therapeutics
Elicio Therapeutics, based in Cambridge, MA, is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to defeat cancer. By combining expertise in materials science and immunology, Elicio is engineering potent Amphiphile immunotherapies, including lymph node targeted cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers. Elicio’s lead Amphiphile vaccine targeting KRAS-driven cancers will begin initial patient studies in pancreatic cancer patients in 2020. These programs are followed by a broad preclinical pipeline of lymph node targeted immunotherapies. For more information, please visit https://elicio.com.
Elicio Therapeutics: Merina Zeller, 617-482-0042, email@example.com